{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T22:41:13Z","timestamp":1793832073378,"version":"4.6.1"},"reference-count":29,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100001818","name":"Research to Prevent Blindness","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001818","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["aaojournal.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Ophthalmology"],"published-print":{"date-parts":[[2020,10]]},"DOI":"10.1016\/j.ophtha.2020.04.017","type":"journal-article","created":{"date-parts":[[2020,4,25]],"date-time":"2020-04-25T02:28:40Z","timestamp":1587781720000},"page":"1345-1359","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":303,"title":["Retinal Vasculitis and Intraocular Inflammation after Intravitreal Injection of Brolucizumab"],"prefix":"10.1016","volume":"127","author":[{"given":"Caroline R.","family":"Baumal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard F.","family":"Spaide","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lejla","family":"Vajzovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K. Bailey","family":"Freund","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3492-4650","authenticated-orcid":false,"given":"Scott D.","family":"Walter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vishak","family":"John","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan","family":"Rich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nauman","family":"Chaudhry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rohit R.","family":"Lakhanpal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick R.","family":"Oellers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thellea K.","family":"Leveque","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bryan K.","family":"Rutledge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4105-983X","authenticated-orcid":false,"given":"Mark","family":"Chittum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7477-2263","authenticated-orcid":false,"given":"Tommaso","family":"Bacci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana Bety","family":"Enriquez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Newman J.","family":"Sund","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric N.P.","family":"Subong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas A.","family":"Albini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ophtha.2020.04.017_bib1","doi-asserted-by":"crossref","first-page":"1997","DOI":"10.1007\/s40265-019-01231-9","article-title":"Brolucizumab: first approval","volume":"79","author":"Markham","year":"2019","journal-title":"Drugs"},{"key":"10.1016\/j.ophtha.2020.04.017_bib2","first-page":"3025","article-title":"Preclinical pharmacology and safety of ESBA1008, a single-chain antibody fragment, investigated as potential treatment for age related macular degeneration","volume":"53","author":"Gaudreault","year":"2012","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.ophtha.2020.04.017_bib3","first-page":"1501","article-title":"Affinity and potency of RTH258 (ESBA1008), a novel inhibitor of vascular endothelial growth factor a for the treatment of retinal disorders","volume":"56","author":"Tietz","year":"2015","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"7","key":"10.1016\/j.ophtha.2020.04.017_bib4","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1016\/j.ophtha.2019.12.031","article-title":"Brolucizumab: evolution through preclinical and clinical studies, and the implications for the management of neovascular age-related macular degeneration","volume":"127","author":"Nguyen","year":"2020","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2020.04.017_bib5","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.ophtha.2019.04.017","article-title":"HAWK and HARRIER: phase 3, multicenter, randomized, double-masked trials of brolucizumab for neovascular age-related macular degeneration","volume":"127","author":"Dugel","year":"2020","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2020.04.017_bib6","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1016\/j.ophtha.2017.03.057","article-title":"Brolucizumab versus aflibercept in participants with neovascular age-related macular degeneration: a randomized trial","volume":"124","author":"Dugel","year":"2017","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2020.04.017_bib7","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1016\/j.ophtha.2015.12.030","article-title":"Single-chain antibody fragment VEGF inhibitor RTH258 for neovascular age-related macular degeneration: a randomized controlled study","volume":"123","author":"Holz","year":"2016","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2020.04.017_bib9","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.ophtha.2013.08.011","article-title":"Intravitreal aflibercept injection for neovascular age related macular degeneration. Ninety-six-week results of the VIEW studies","volume":"121","author":"Schmidt-Erfurth","year":"2014","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2020.04.017_bib10","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1007\/s10792-016-0241-4","article-title":"Safety and complications of intravitreal injections performed in an Asian population in Singapore","volume":"37","author":"Xu","year":"2017","journal-title":"Int Ophthalmol"},{"key":"10.1016\/j.ophtha.2020.04.017_bib11","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1016\/j.ophtha.2016.02.046","article-title":"Comprehensive review of ocular and systemic safety events with intravitreal aflibercept in randomized controlled clinical trials","volume":"123","author":"Kitchens","year":"2016","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2020.04.017_bib12","author":"Lloyd"},{"issue":"11","key":"10.1016\/j.ophtha.2020.04.017_bib14","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1097\/00006324-197611000-00006","article-title":"New design principles for visual acuity letter charts","volume":"53","author":"Bailey","year":"1976","journal-title":"Am J Optom Physiol Opt"},{"issue":"6","key":"10.1016\/j.ophtha.2020.04.017_bib15","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/S0002-9394(14)73474-9","article-title":"Relative letter and position difficulty on visual acuity charts from the Early Treatment Diabetic Retinopathy Study","volume":"116","author":"Ferris","year":"1993","journal-title":"Am J Ophthalmol"},{"issue":"2","key":"10.1016\/j.ophtha.2020.04.017_bib16","doi-asserted-by":"crossref","first-page":"69","DOI":"10.3109\/09286586.2015.1122067","article-title":"Intraocular inflammation following intravitreal injection of anti-VEGF medications for neovascular age-related macular degeneration","volume":"23","author":"Knickelbein","year":"2016","journal-title":"Ophthalmic Epidemiol"},{"key":"10.1016\/j.ophtha.2020.04.017_bib17","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1001\/jamaophthalmol.2014.5650","article-title":"Postmarketing analysis of aflibercept-related sterile intraocular inflammation","volume":"133","author":"Hahn","year":"2015","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.ophtha.2020.04.017_bib18","doi-asserted-by":"crossref","first-page":"71","DOI":"10.3109\/09286586.2015.1090004","article-title":"Severe ocular inflammation following ranibizumab or aflibercept injections for age-related macular degeneration: a retrospective claims database analysis","volume":"23","author":"Souied","year":"2016","journal-title":"Ophthalmic Epidemiol"},{"key":"10.1016\/j.ophtha.2020.04.017_bib19","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1097\/ICB.0000000000000601","article-title":"Hemorrhagic vasculitis and retinopathy heralding as an early sign of bacterial endophthalmitis after intravitreal injection","volume":"13","author":"Conrady","year":"2019","journal-title":"Retin Cases Brief Rep"},{"key":"10.1016\/j.ophtha.2020.04.017_bib20","first-page":"100680","article-title":"Retinal arterial vasculitis following intravitreal brolucizumab administration","volume":"18","author":"Haug","year":"2020","journal-title":"AJO Case Reports"},{"key":"10.1016\/j.ophtha.2020.04.017_bib21","first-page":"100687","article-title":"Severe vision loss secondary to retinal arteriolar occlusions after multiple intravitreal brolucizumab administrations","volume":"18","author":"Jain","year":"2020","journal-title":"AJO Case Reports"},{"key":"10.1016\/j.ophtha.2020.04.017_bib23","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1097\/IIO.0000000000000072","article-title":"The role of gender in uveitis and ocular inflammation","volume":"55","author":"Yeung","year":"2015","journal-title":"Int Ophthalmol Clin"},{"key":"10.1016\/j.ophtha.2020.04.017_bib24","doi-asserted-by":"crossref","first-page":"146","DOI":"10.3109\/02713683.2014.932388","article-title":"Gender disparities in ocular inflammatory disorders","volume":"40","author":"Chan","year":"2015","journal-title":"Curr Eye Res"},{"issue":"8","key":"10.1016\/j.ophtha.2020.04.017_bib25","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.2105\/AJPH.2007.124537","article-title":"Adverse event detection in drug development: recommendations and obligations beyond phase 3","volume":"98","author":"Berlin","year":"2008","journal-title":"Am J Public Health"},{"issue":"4","key":"10.1016\/j.ophtha.2020.04.017_bib29","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1038\/nrd3003","article-title":"The safety and side effects of monoclonal antibodies","volume":"9","author":"Hansel","year":"2010","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.ophtha.2020.04.017_bib30","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1016\/j.ophtha.2015.03.016","article-title":"Postoperative hemorrhagic occlusive retinal vasculitis. Expanding the clinical spectrum and possible association with vancomycin","volume":"122","author":"Witkin","year":"2015","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2020.04.017_bib31","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/j.ophtha.2016.11.042","volume":"124","author":"Witkin","year":"2017","journal-title":"Eyes. Ophthalmology"},{"key":"10.1016\/j.ophtha.2020.04.017_bib32","first-page":"1298473","article-title":"Immunogenicity of biotherapeutics: causes and association with posttranslational modifications","volume":"2016","author":"Kuriakose","year":"2016","journal-title":"J\u00a0Immunol Res"},{"issue":"4","key":"10.1016\/j.ophtha.2020.04.017_bib33","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1038\/s41433-019-0584-y","article-title":"Abicipar pegol\u2013a novel anti-VEGF therapy with a long duration of action","volume":"34","author":"Moisseiev","year":"2020","journal-title":"Eye (Lond)"},{"issue":"2","key":"10.1016\/j.ophtha.2020.04.017_bib34","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1136\/bjophthalmol-2011-301087","article-title":"Macular ischaemia: a contraindication for anti-VEGF treatment in retinal vascular disease?","volume":"96","author":"Manousaridis","year":"2012","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.ophtha.2020.04.017_bib35","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1016\/S0161-6420(88)32951-9","article-title":"Acute multifocal hemorrhagic retinal vasculitis","volume":"95","author":"Blumenkranz","year":"1998","journal-title":"Ophthalmology"}],"container-title":["Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0161642020303717?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0161642020303717?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T14:09:07Z","timestamp":1758982147000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0161642020303717"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10]]},"references-count":29,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2020,10]]}},"alternative-id":["S0161642020303717"],"URL":"https:\/\/doi.org\/10.1016\/j.ophtha.2020.04.017","relation":{},"ISSN":["0161-6420"],"issn-type":[{"value":"0161-6420","type":"print"}],"subject":[],"published":{"date-parts":[[2020,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Retinal Vasculitis and Intraocular Inflammation after Intravitreal Injection of Brolucizumab","name":"articletitle","label":"Article Title"},{"value":"Ophthalmology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ophtha.2020.04.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 by the American Academy of Ophthalmology","name":"copyright","label":"Copyright"}]}}